Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03735433 · ClinicalTrials.gov registry record · Phase 4
The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
A Phase 4 study, sponsored by Ohio State University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 152
- Enrollment target
NCT03735433 is a Phase 4 study that was terminated before completion, run by Ohio State University. The registered enrollment target is 152 participants.
The verdict
NCT03735433, a Phase 4 study, was terminated before completion, sponsored by Ohio State University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 152 participants
- Enrollment target
Study Summary
Low dose aspirin (LDA) is used for preeclampsia (PE) prevention in high risk women, but the precise mechanism and optimal dose is not known. Evidence in the non-obstetric literature suggests AR may be more common among patients with a high body mass index (BMI). Recent unpublished data showed that LDA substantially lowers TxB2 levels regardless of BMI, but rates of complete platelet inhibition are lower in women with BMI ≥40. This data suggests that higher doses of ASA may be necessary in obese women. Therefore we plan determine if use of 162mg compared to the traditional 81mg ASA decreased rates of preeclampsia in women considered high risk for developing preclampsia.
Interventions
- DRUG 162mg aspirin dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03735433
The ClinicalTrials.gov registry entry for NCT03735433 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 162mg aspirin dose is the first listed.
NCT03735433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03735433 about?
NCT03735433 is a clinical study titled "The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia". Low dose aspirin (LDA) is used for preeclampsia (PE) prevention in high risk women, but the precise mechanism and optimal dose is not known. Evidence in the non-obstetric literature suggests AR may be more common among patients with a high body mass index (BMI). Recent unpublished data showed that L...
What is the current status of trial NCT03735433?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 152 participants. The study started on 2019-01-15. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT03735433?
The interventions under investigation include: 162mg aspirin dose (DRUG).
Who is sponsoring clinical trial NCT03735433?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.